Small clinical study claims memory loss from Alzheimer’s can be reversed

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

A small clinical trial is giving patients diagnosed with Alzheimer’s new hope.

According to Science Alert, a clinical trial of 10 patients with early stages of the disease has shown that memory loss and cognitive impairment can be reversed.

The study investigated the effects of a new personalized treatment called Metabolic Enhancement for Neurodegeneration, or MEND.

The treatment consists of 36 different factors including changes in diet, exercise, sleeping habits, vitamins, brain stimulation therapy and the integration of certain drugs.

“The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,” said Dale Bredsen, with the University of California, Los Angeles.

All but one of the patients carried at least one copy of the APOE4 allele, which puts them at a genetic risk for the disease.

Five of the patients carried two copies of the gene, which increased their risk for the disease 10 fold.

“All of these patients had either well-defined mild cognitive impairment, subjective cognitive impairment, or had been diagnosed with Alzheimer’s disease before beginning the program,” Bredsen told Science Alert. “Follow up testing showed some of the patients going from abnormal to normal.”

Science Alert says one woman regained her ability to speak two different languages after taking the treatment for nine months and remains “asymptomatic.”

However, it also states that the gains started to decline once the patients stopped treatment.